reports
Teva to Host Conference Call to Discuss Fourth Quarter and Full Year 2...
Teva to Host Conference Call to Discuss Fourth Quarter and Full Year 2024 Financial Results and 2025 Financial Guidance at 8 a.m. ET on January 29, 2025 TEL AVIV, Israel, Dec. 20, 2024 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will issue a press release on its fourth quarter and full year 2024 financial results, as well as on its financial guidance for 2025, on Wednesday, January 29, 2025, at 7:00 a.m. ET. Following the release, Teva will conduct a conference call and live webcast on the same day, at 8:00 a.m. ET. In order ...
Teva and Sanofi Announce Duvakitug (Anti-TL1A) Positive Phase 2b Resul...
Teva and Sanofi Announce Duvakitug (Anti-TL1A) Positive Phase 2b Results Demonstrating Best-in-Class Potential in Ulcerative Colitis and Crohn’s Disease Teva hosting investor call today at 8:00 a.m. ET (U.S.) Primary endpoints met in ulcerative colitis (UC) and Crohn’s disease (CD), the most common forms of inflammatory bowel disease (IBD)Primary endpoint results in UC and CD for high dose represent the highest achieved with any TL1A monoclonal antibodySanofi and Teva plan to initiate Phase 3 development in IBD, pending regulatory discussions PARSIPPANY, N.J. and PARIS, Dec. 1...
Teva Announces New Patient Access Program with Direct Relief to Provid...
Teva Announces New Patient Access Program with Direct Relief to Provide Access to Inhalers for Uninsured Patients Teva to provide two generic inhaler products to Direct Relief for its network of free and charitable clinicsThe program, launching this month, will run for a minimum of three years PARSIPPANY, N.J., Dec. 11, 2024 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, Inc., a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), announced today the launch of a new patient access program, in partnership with Direct Relief, to supply inhalers to eligible patients i...
- Felix Fischer
PFD PREMIER FOODS PLC
AMS AMS AG
RR. ROLLS-ROYCE HOLDINGS PLC
CO CASINO GUICHARD-PERRACHON SA
VK VALLOUREC SA
TLW TULLOW OIL PLC
EO FAURECIA SA
105I SAPPI LIMITED
TEVA.N TEVA PHARMACEUTICAL INDUSTRIES LIMITED SPONSORED ADR
LBTYA LIBERTY GLOBAL PLC CLASS A
CSTM CONSTELLIUM SE CLASS A
CCK CROWN HOLDINGS INC.
RXL REXEL SA
DBG DERICHEBOURG SA
725180 STADA ARZNEIMITTEL AG
NOKIA NOKIA OYJ
TNET TELENET GROUP HOLDING NV
TUI1 TUI AG
NEX NEXANS SA
VED VEDANTA RESOURCES PLC
VCP VICTORIA PLC
AF AIR FRANCE-KLM SA
BBD.B BOMBARDIER INC. CLASS B
SYNT SYNTHOMER PLC
INTRUM INTRUM AB
888 888 HOLDINGS PLC
IPF INTERNATIONAL PERSONAL FINANCE PLC
ENQ ENQUEST PLC
EDR EDREAMS ODIGEO SA
TC1 TELE COLUMBUS AG
9984 SOFTBANK GROUP CORP.
103M SASOL LIMITED
TIT TELECOM ITALIA S.P.A.
REC RECORDATI INDUSTRIA CHIMICA E FARMACEUTICA S.P.A.
TGS TGS-NOPEC GEOPHYSICAL COMPANY ASA
TALK TALKTALK TELECOM GROUP PLC
TATAMOTORS TATA MOTORS LIMITED
PL8 PLAYTECH PLC
ARW ARROW GLOBAL GROUP PLC
NEMAKA NEMAK S.A.B. DE C.V.
SPIE SPIE SA
CEXA CEMEX SAB DE CV (ADR)
ARD ARDAGH GROUP S.A. CLASS A
PFL PFLEIDERER GROUP SA
DIGI DIGI COMMUNICATIONS NV
CDR CODERE S.A.
GAME GAMENET GROUP SPA
AML ASTON MARTIN LAGONDA GLOBAL HOLDINGS PLC
TIFS TI FLUID SYSTEMS
NEXI NEXI S.P.A.
AXA AXACTOR SE
BORR SECURITAS DIRECT AB CL B
BORR DRILLING LTD
- Ian Wong
- Felix Fischer
- Ian Wong
- Jayanth Kandalam
- Peter Low
- Si Yong Ng
Teva Announces Agreement to Divest Teva-Takeda, its Business Venture i...
Teva Announces Agreement to Divest Teva-Takeda, its Business Venture in Japan Teva entered into an agreement with JKI Co., Ltd. (“JKI”) established by the fund managed and operated by private equity firm J-Will Partners Co., Ltd. ("J-Will”), through which JKI will acquire Teva-TakedaThe agreement is aligned with Teva's Pivot to Growth strategy to focus its businessThe expected divestment of Teva-Takeda, Teva's business venture in Japan, which includes generics products and legacy products, will allow Teva to focus on bringing its innovative medicines to the Japanese market TEL AVIV, Israel...
Teva präsentiert positive Wirksamkeits- und Sicherheitsdaten von AJOVY...
Teva präsentiert positive Wirksamkeits- und Sicherheitsdaten von AJOVY® (Fremanezumab) zur Vorbeugung episodischer Migräne bei Kindern und Jugendlichen aus der Phase-III-Studie SPACE AJOVY® (Fremanezumab) reduzierte die monatlichen Migränetage (MMD) und monatlichen Kopfschmerztage (MHD) im Vergleich zu Placebo über einen Zeitraum von 12 Wochen bei pädiatrischen Patienten im Alter von 6 bis 17 Jahren signifikant.1Wirksamkeit im Einklang mit Phase-III-Zulassungs- und Real-World-Evidence-Studien zu Fremanezumab bei Erwachsenen, im Rahmen derer keine neuen Sicherheitsbedenken festgestellt wurde...
Teva présente des données positives sur l’efficacité et la sécurité d’...
Teva présente des données positives sur l’efficacité et la sécurité d’emploi d’AJOVY® (frémanézumab) pour la prévention de la migraine épisodique chez les enfants et les adolescents dans le cadre de l’essai clinique de phase III SPACE AJOVY® (frémanézumab) a permis de réduire de manière significative le nombre de jours de migraine mensuels (MMD, de l’anglais « monthly migraine days ») et le nombre de jours de céphalées mensuels (MHD, de l’anglais « monthly headache days ») par rapport au placebo sur une période d’administration de 12 semaines chez des patients pédiatriques âgés de 6 à 17 an...
Teva to Present at the 7th Annual Evercore ISI HealthCONx Conference
Teva to Present at the 7th Annual Evercore ISI HealthCONx Conference TEL AVIV, Israel, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that Richard Francis, Teva's President and CEO, and Eric Hughes, Teva’s Executive Vice President of Global R&D and Chief Medical Officer, will present at the 7th Annual Evercore ISI HealthCONx Conference on Thursday, December 5, 2024. The presentation will begin at 8:20 A.M. Eastern Time. To access a live webcast of the presentation, visit Teva’s Investor Relations website at . An archived versi...
- Ian Wong
- Felix Fischer
- Haidje Rustau
- Ian Wong
- Jayanth Kandalam
- Si Yong Ng
- Tanvi Arora
Lucror Analytics - Morning Views Europe
In today's Morning Views publication we comment on developments of the following high yield issuers: Odigeo, Engineering Group, Teva, Versuni (formerly Philips Domestic Appliances), Alain Afflelou, Eircom, Iliad, Borr Drilling, Ithaca Energy, Tullow Oil, Victoria, TUI Cruises, Axactor, McLaren, EVOCA, Flos B&B Italia (formerly International Design Group)
Teva to Present at the Jefferies London Healthcare Conference
Teva to Present at the Jefferies London Healthcare Conference TEL AVIV, Israel, Nov. 08, 2024 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that Richard Francis, Teva's President and CEO, will present at the Jefferies London Healthcare Conference on Tuesday, November 19, 2024. The presentation will begin at 8:30 A.M. Greenwich Mean Time (3.30 A.M. Eastern Time). To access a live webcast of the presentation, visit Teva’s Investor Relations website at . An archived version of the webcast will be available within 24 hours after the end of...
- Felix Fischer
- Ian Wong
- Felix Fischer
- Ian Wong
- Jayanth Kandalam
- Peter Low
- Tanvi Arora
Lucror Analytics - Morning Views Europe
In today's Morning Views publication we comment on developments of the following high yield issuers: Recordati, Teva, Novelis, Bombardier, Selecta, Hapag-Lloyd, Italmatch Chemicals, Kem One, Cirsa, Nexans, ASK Chemicals, Borr Drilling, Encore Capital (formerly Cabot)
Teva Announces Strong Financial Results for the Third Quarter of 2024,...
Teva Announces Strong Financial Results for the Third Quarter of 2024, led by Generics Performance and Innovative Portfolio Growth; Raises 2024 Financial Outlook including on Revenues, Adjusted EBITDA and Non-GAAP EPS For an accessible version of this Press Release, please visit Q3 2024 revenues of $4.3 billion reflect an increase of 13% in U.S. dollars, or 15% in local currency terms, compared to Q3 2023.AUSTEDO® – shows continued growth, U.S. revenues of $435 million in Q3 2024, an increase of 28% compared to Q3 2023; reaffirming 2024 revenue outlook of ~$1.6 billion.AJOVY® – global rev...
- Felix Fischer
- Ian Wong
- Felix Fischer
- Ian Wong
- Jayanth Kandalam
- Peter Low
Teva Presents New Tardive Dyskinesia Data at Psych Congress 2024 from ...
Teva Presents New Tardive Dyskinesia Data at Psych Congress 2024 from the IMPACT-TD Registry, Revealing Differences in Patient Experience Based on Underlying Psychiatric Condition IMPACT-TD Registry, the largest study evaluating holistic effects of tardive dyskinesia (TD), highlights that there is a high burden of TD on quality of life regardless of a person’s underlying mental health conditionRegistry revealed fewer patients with psychotic disorders (36%) received TD diagnoses compared to those with mood disorders (50%)Teva continues to further innovations in mental health and progress rea...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.